In the 2022 to 2023 season, a significant spike in respiratory syncytial virus (RSV) cases was observed. As the 2023 to 2024 RSV season began, concerns arose that similarly high rates of RSV incidence and hospitalization would be reported. A panel of clinicians gathered to address these concerns and report preliminary findings.
Takeaways
- The 2022 to 2023 season saw a significant spike in RSV cases. In 2023 to 2024, while the onset was slightly earlier than expected, it followed a more regular seasonality pattern. However, the rate of reported cases remained high.
- Pregnant patients exhibited increased awareness about RSV and were more receptive to vaccination. However, new mothers and the older population showed gaps in understanding and access, with challenges including cost barriers, vaccine shortages, and lack of clear recommendations.
- There is a lack of therapeutics against RSV, emphasizing the critical need for vaccination. The panel discussed nirsevimab as a promising option due to its convenience, but its availability was hindered by shortages. The severity of RSV, especially in older patients, was emphasized by data showing increased morbidity and mortality.
- Vaccine fatigue among patients, combined with the increasing number of recommended vaccines, poses challenges. The possibility of combining vaccines was discussed as a potential solution, although more research is needed.
- There is a pressing need for continued education about RSV risks, the importance of vaccination, and interventions available. Clinicians play a crucial role in promoting vaccines, ensuring accessibility, and addressing the specific needs and risks associated with different patient groups.
According to William Muller, MD, PhD, an early RSV season was observed in 2022. Cases began in August and September and peaked in October and November. In 2023, rises in RSV case rates began in November, with peaks expected in January.
While this is slightly earlier than expected, it is closer to the regular seasonality observed before 2022. However, the rates of reported cases are still high. Neil Silverman, MD, reported a rise in the rate of positive tests from 5% to 8% in California in the week prior to the panel.
Silverman also discussed counseling pregnant patients about the risks to newborns and mothers. He has observed improved awareness about RSV in these patients compared to other conditions, as well as less resistance toward accepting vaccination against RSV.
Laura Riley, MD, reported that while many pregnant women and mothers with toddlers sought RSV vaccination, these behaviors were less common among new mothers. This indicates a need to education new mothers on the importance of vaccination.
A significant amount of education on the RSV vaccine is needed in the older population, according to Robert Hopkins, MD. RSV is common across all age groups, but not all receive equal education on benefits, value, and using the appropriate product.
Discussion about the monoclonal antibody for newborns is also difficult because of a national shortage. Clinicians need to address this shortage with their patients and express that they are putting forth their best effort to help them and their children.
Insurers are also creating challenges for patients who are unable to access the vaccine because of cost.Hopkins reported that approximately 15% to 20% of birthing hospitals participatein the Medicaid VFC program, indicating disparities in vaccine availability.
Sallie Permar, MD, PhD, noted a rise in children hospitalized with RSV because they were unable to access the vaccine. This can lead to preventable intensive care unit admission.
The panel also discussed the convenience of nirsevimab (Beyfortus; Sanofi) for managing RSV. Nirsevimab is more straightforward than alternative treatment options such as palivizumab, as it is single use rather than injected monthly and is cheaper. However, because of shortages, clinicians are unable to provide nirsevimab to their patients.
A rush to make therapeutics available too close to the season caused the supply of medication to be unable to meet the demand. Additionally, Riley noted how RSV was not as prevalent of a concern as influenza or COVID-19 prior to 2022. This caused RSV to be of low concern for many clinicians until the spike in cases, leaving many unprepared to manage patients and underscoring the importance of education.
Riley also expressed a concern over patients failing to understand the importance of vaccination against RSV in future seasons. If cases decrease significantly, some patients may not consider it important to get vaccinated against the disease. RSV is a severe condition, leading to 10% of hospitalizations in children aged over 2 years. Interventions must be implemented to reduce this severity.
Permar noted that the RSV vaccine was developed following a season where pediatric wards were filled with patients who presented with RSV. Similarly to conditions such as COVID-19, RSV should be treated as an emergency every year.